Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

JOURNAL ARTICLE published 15 February 2016 in Clinical Cancer Research

Research funded by The Donald A Adam Comprehensive Melanoma Research Center, NCI Cancer Center Support Grant, NCI (RO1CA129594,FDARO1FD-003511,P30 CA076292)

Authors: Morganna Freeman-Keller | Youngchul Kim | Heather Cronin | Allison Richards | Geoffrey Gibney | Jeffrey S. Weber